Lakewood-Amedex Biotherapeutics Inc. (LABT) is a clinical-stage biopharmaceutical company developing small molecule antimicrobials to address antimicrobial resistance (AMR). The company has generated zero revenue from product sales as of the quarter ended March 31, 2026, and finances operations through equity offerings, debt financings, and potential future collaborations or license agreements. Originally incorporated in Delaware on July 11, 2006 as Nu Pharmas, Inc., the company redomiciled as a Nevada corporation on June 5, 2025 and is headquartered in University Park, Florida. Its lead program centers on the Bisphosphocin class of molecules, discovered during early oligonucleotide research and pursued since 2012. Total operating expenses were $886,750 for Q1 2026, split between research and development ($182,147) and general and administrative costs ($704,603). Cash and cash equivalents stood at $11.7 thousand as of March 31, 2026. The company has incurred operating losses and negative cash flows since inception.

Revenue model

No product revenue as of March 31, 2026. Operations funded through equity offerings, debt financings, and potential future collaborations, license agreements, or similar arrangements.

Products and services

Bisphosphocin class of small molecule antimicrobials targeting antimicrobial resistance (AMR). No products approved for sale as of the 10-Q filed May 22, 2026.

Customers and end markets

No commercial customers as of March 31, 2026. Target end market is treatment of infections caused by antimicrobial-resistant pathogens.

Value-chain role

Pre-revenue drug discovery and development company. Conducts clinical and pre-clinical research internally. R&D expenses for Q1 2026 included $15,733 in clinical and pre-clinical expenses and $162,784 in personnel-related expenses.

Geographic exposure

Headquartered in University Park, Florida. No disclosed international operations.

Source: SEC 10-Q, filed 2026-05-22

Industry: Pharmaceutical Preparations